Wave Life Sciences
🇸🇬Singapore
- Country
- 🇸🇬Singapore
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 268
- Market Cap
- $704.7M
- Introduction
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
Phase 1
Terminated
- Conditions
- Huntington's Disease
- Interventions
- Drug: WVE-120102Drug: Placebo
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT03225846
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
🇦🇺Westmead Hospital, Sidney, New South Wales, Australia
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
Phase 1
Terminated
- Conditions
- Huntington's Disease
- Interventions
- Drug: WVE-120101Drug: Placebo
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT03225833
- Locations
- 🇦🇺
Royal Brisbane & Women's Hospital, Herston, Queensland, Australia
🇦🇺Royal Melbourne Hospital, Carlton, Victoria, Australia
🇦🇺Monash Health, Clayton, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath